Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) Latest Company News

Sep 18, 2026, 10:26 UTC
Shanghai RAAS Blood Products' wholly-owned subsidiary Nanyue Biopharmaceutical received a drug registration certificate from the National Medical Products Administration for human fibrinogen injection (0.5g/vial) for congenital fibrinogen deficiency or absence.
Source:
- finance.sina.cn
Sep 16, 2026, 11:51 UTC
Shanghai RAAS Blood Products announced that its investigational SR604 injection entered Phase III clinical trials for hemophilia A/B after its Phase I/II study met the primary endpoint, with the trial registered as CTR20263539 on China's drug clinical trial registration platform.
Source:
- finance.sina.cn
Sep 9, 2026, 09:25 UTC
Shanghai RAAS announced a share buyback plan of 250 million to 500 million yuan to cancel shares and reduce registered capital.
Source:
- finance.sina.cn
Aug 28, 2026, 03:50 UTC
Shanghai RAAS stated that Guangxi RAAS is in trial production and has not yet officially commenced production.
Source:
- finance.sina.cn
Aug 24, 2026, 12:17 UTC
Shanghai RAAS reported its first-half 2026 results, with net profit attributable to shareholders of 661 million yuan, down 35.80% year-on-year.
Source:
- finance.sina.cn
- wap.eastmoney.com
Aug 21, 2026, 12:18 UTC
Shanghai RAAS's subsidiary Guangxi RAAS Biopharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application for Protein C, a treatment for congenital protein C deficiency.
Source:
- finance.sina.cn
Jul 22, 2026, 10:16 UTC
Shanghai RAAS announced the Phase II clinical trial progress of SR604 injection for congenital factor VII deficiency on the National Medical Products Administration drug trial registration platform.
Source:
- finance.sina.cn

002252.SZ

Shanghai RAAS Blood Products' wholly-owned subsidiary Nanyue Biopharmaceutical received a drug registration certificate from the National Medical Products Administration for human fibrinogen injection (0.5g/vial) for congenital fibrinogen deficiency or absence.

Shanghai RAAS Blood Products announced that its investigational SR604 injection entered Phase III clinical trials for hemophilia A/B after its Phase I/II study met the primary endpoint, with the trial registered as CTR20263539 on China's drug clinical trial registration platform.

Shanghai RAAS announced a share buyback plan of 250 million to 500 million yuan to cancel shares and reduce registered capital.

Shanghai RAAS stated that Guangxi RAAS is in trial production and has not yet officially commenced production.

Shanghai RAAS reported its first-half 2026 results, with net profit attributable to shareholders of 661 million yuan, down 35.80% year-on-year.

Shanghai RAAS's subsidiary Guangxi RAAS Biopharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application for Protein C, a treatment for congenital protein C deficiency.

Shanghai RAAS announced the Phase II clinical trial progress of SR604 injection for congenital factor VII deficiency on the National Medical Products Administration drug trial registration platform.